1. Germany Stocks

  2. •

    Healthcare

  3. •

    Medical - Specialties
Bayer AG

Bayer AG

BAYNN.MX
Bayer AGMX flagMexican Stock Exchange
779.00
MXN
- -
- -
765.31BMarket Cap
Bayer AG
BAYNN.MX
(Mexican Stock Exchange)

Recent

price

779.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
42.43
44.17
48.06
48.56
49.99
55.73
41.97
39.56
39.06
44.36
42.14
44.87
51.65
48.49
47.44
46.39
46.05
Revenue per Share
1.57
2.99
2.91
3.86
4.14
4.97
5.44
8.29
1.8
4.17
-10.68
1.02
4.22
-2.99
-2.6
-3.68
-2.19
Basic EPS, GAAP
5.15
4.17
3.15
3.64
4.16
5.29
7.82
6.52
5.66
5.66
2.53
2.52
4.22
2.41
4.67
3.5
2.69
Free Cash Flow per Basic Share
1.4
1.5
1.65
1.9
2.1
2.26
2.55
2.67
2.56
2.66
2.82
2.03
2.02
2.42
0.13
0.13
0.13
Dividend per Share
2.56
2.56
2.56
2.56
2.56
2.56
2.54
2.39
2.54
2.56
2.56
2.56
2.56
2.56
2.56
2.56
2.56
Book Value per Share
-1.53
-0.22
-0.25
2.45
-13.04
-7.05
2.42
11.79
-31.1
-27.08
-31.72
-33.79
-25.35
-22.99
-20.44
-23.02
-20.25
Tangible Book Value per Share
827
827
827
827
827
827
833
885
941
982
982
982
982
982
982
982
982
Basic Weighted Avg Shares
35,088
36,528
39,741
40,157
41,339
46,085
34,943
35,015
36,742
43,545
41,400
44,081
50,739
47,637
46,606
45,575
45,242
Sales/Revenue/Turnover
7.78
11.62
13.2
12.68
13.59
14.74
17.22
17.45
-0.5
10.82
-1.72
15.67
14.45
16.87
7.14
13.47
16.23
Operating Margin (%)
3,556
2,769
2,988
2,896
2,920
3,332
3,063
2,660
6,241
5,367
13,259
3,056
6,503
10,020
8,783
2,785
2,865
Depreciation Expense
1,301
2,470
2,403
3,189
3,426
4,110
4,531
7,336
1,695
4,091
-10,495
1,000
4,150
-2,941
-2,552
-3,620
-2,156
Net Income, GAAP
23.88
26.49
22.76
24.27
24.26
23.36
21.31
29.04
26.3
15.53
- -
50.05
10.79
- -
- -
- -
7.43
Effective Tax Rate (%)
3.71
6.76
6.05
7.94
8.29
8.92
12.97
20.95
4.61
9.39
-25.35
2.27
8.18
-6.17
-5.48
-7.94
-4.77
Profit Margin (%)
7,483
6,678
5,906
5,005
6,724
6,841
11,910
16,480
7,820
9,224
-1,093
3,175
2,676
8,099
5,492
326
1,841
Working Capital
9,582
7,686
6,706
5,044
17,797
16,332
15,375
12,158
37,708
36,907
33,198
36,478
33,781
38,170
35,491
31,806
- -
LT Debt
18,896
19,271
18,551
20,804
20,218
25,445
31,897
36,861
46,064
47,433
30,675
33,168
38,926
33,078
32,045
26,063
28,962
Total Equity
6.8
10.35
13.98
13.78
12.44
12.18
9.81
8.53
-0.2
4.57
- -
4.67
8.47
- -
- -
- -
- -
Return on Invested Capital (%)
9.4
24.69
25.66
37.72
26.69
22.58
22.41
38.55
9.65
13.29
- -
3.82
13.44
- -
- -
- -
25.88
Return on Capital (%)
61.45
116.67
113.51
150.64
161.83
194.14
214.03
346.53
75.27
166.91
-417.3
39.76
165.01
-116.94
-101.47
-143.94
-85.73
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
4,647
- -
LT Borrowings
- -
30,779
- -
LT Finance Leases
- -
1,027
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
982
982
982
Market Capitalization
27,702
35,655
37,070

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
32,881
32,911
35,301
Cash, Cash Equivalents & STI
7,242
7,856
6,660
Accounts Receivable, Net
9,988
9,077
12,907
Inventories
12,332
12,335
12,014
Total Current Liabilities
28,957
32,585
33,460
Payables & Accruals
- -
- -
- -
ST Debt
- -
4,647
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
2.22%
-2.26%
-18.67%
Free Cash Flow
7.19%
18.61%
-24.99%
Net Income, GAAP
-15.67%
12.64%
41.85%
Sales/Revenue/Turnover
0.57%
2.22%
-2.21%
Total Cash Common Dividend
-6.48%
-21.22%
-3.05%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
13,765
11,144
9,968
11,729
46,606
2025
13,738
10,739
9,660
11,438
45,575
2026
13,405
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2.04
-0.03
-4.26
- -
-2.6
2025
1.32
-0.2
-0.98
- -
-3.68
2026
2.81
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.12
0.01
- -
0.13
2025
- -
0.11
0.01
- -
0.13
2026
- -
- -
- -
- -
- -
Similar Companies
InBody Co.,Ltd (041830.KQ)
Coloplast A/S (CBHD.DE)
Hemant Surgical Industries Ltd. (HSIL.BO)
Sincere Co. Ltd. (7782.T)
Hass (450330.KQ)
Mani, Inc. (7730.T)
Business
Bayer AG (BAYNN.MX) operates as a global life sciences company focused on healthcare and nutrition, with core divisions in Pharmaceuticals, Crop Science, and Consumer Health. The Pharmaceuticals division develops and markets prescription therapeutics in oncology including Targeted Alpha Therapies and drugs such as Nubeqa (darolutamide), cardiovascular treatments like Kerendia (finerenone), women's health products, hematology, ophthalmology, cell and gene therapies, and contrast agents for diagnostic imaging; Crop Science offers seeds and plant traits including corn hybrids, crop protection solutions such as herbicides like Liberty, pesticides, nonagricultural pest control, and digital agriculture services; Consumer Health provides nonprescription over-the-counter products in dermatology, dietary supplements, analgesics, gastrointestinal remedies, cold/allergy/sinus/flu treatments, foot care, and sun protection. Founded in 1863 and headquartered in Leverkusen, Germany, Bayer conducts operations across North America, Europe, Africa, Middle East, Asia-Pacific, and Latin America, employing approximately 92,800 people and generating revenue of about $50.4 billion in 2024. In recent developments, Bayer extended its strategic partnership with Ginkgo Bioworks in 2025 to advance microbial nitrogen fixation, crop protection, and sustainability technologies originating from their 2017 collaboration; entered a up to $1.3 billion licensing agreement with Kumquat Biosciences in August 2025 for a KRAS G12D inhibitor cancer drug candidate targeting pancreatic, colorectal, and lung cancers; partnered with PanTera in 2024 for next-generation radiopharmaceutical starting materials; signed technology transfer agreements such as with Dhanuka Agritech in early 2025 for active ingredients Iprovalicarb and Triadimenol; announced plans for multiple blockbuster product launches in 2025 including Beyonttra (acoramidis); and implemented a five-year Crop Science strategy to streamline portfolios, optimize production, and target over €3.5 billion in incremental sales from innovation by 2030 amid cost pressures.